Switching Antiretroviral Therapy in the Setting of Virologic Suppression: A Why and How-To Guide
- PMID: 31255385
- DOI: 10.1016/j.idc.2019.04.003
Switching Antiretroviral Therapy in the Setting of Virologic Suppression: A Why and How-To Guide
Abstract
This review provides a synopsis of key clinical considerations for switching antiretroviral therapy (ART) for individuals with human immunodeficiency virus who have maintained a routinely suppressed viral load. There may be benefits but also risks involved in every ART regimen change, so strategies for prioritizing individuals for a switch based on the specific antiretroviral agents in the regimen are discussed, along with approaches to ensure maintenance of viral suppression after treatment modifications. Controversial and evolving questions in the area of ART switches and simplifications are also considered.
Keywords: Antiretroviral agents; Drug substitution; HIV; Viral load.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Ready for HIV Dual Therapy? - New Data from International HIV/AIDS Society 2017.AIDS Rev. 2017 Oct-Dec;19(3):167-172. AIDS Rev. 2017. PMID: 29019353
-
Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?HIV Med. 2019 Apr;20 Suppl 4:2-12. doi: 10.1111/hiv.12716. HIV Med. 2019. PMID: 30821898 Review.
-
Optimizing Antiretroviral Therapy in Treatment-Experienced Patients Living with HIV: A Critical Review of Switch and Simplification Strategies. An Opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy.J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219867325. doi: 10.1177/2325958219867325. J Int Assoc Provid AIDS Care. 2019. PMID: 31516088 Free PMC article.
-
What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies.Pediatr Infect Dis J. 2019 Apr;38(4):400-405. doi: 10.1097/INF.0000000000002156. Pediatr Infect Dis J. 2019. PMID: 30882732 Free PMC article.
-
New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.AIDS Rev. 2018;20(4):179-186. doi: 10.24875/AIDSRev.M18000026. AIDS Rev. 2018. PMID: 30548024 Review.
Cited by
-
Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.J Antimicrob Chemother. 2024 May 2;79(5):1133-1141. doi: 10.1093/jac/dkae083. J Antimicrob Chemother. 2024. PMID: 38546974 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical